Timothy Lee - Ascendis Pharma Director Relations
| A1SN34 Stock | BRL 56.10 0.00 0.00% |
Insider
Timothy Lee is Director Relations of Ascendis Pharma AS
| Phone | 45 70 22 22 44 |
| Web | https://ascendispharma.com |
Timothy Lee Latest Insider Activity
Tracking and analyzing the buying and selling activities of Timothy Lee against Ascendis Pharma stock is an integral part of due diligence when investing in Ascendis Pharma. Timothy Lee insider activity provides valuable insight into whether Ascendis Pharma is net buyers or sellers over its current business cycle. Note, Ascendis Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ascendis Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Timothy Lee over a month ago Acquisition by Timothy Lee of 300000 shares of Invivyd subject to Rule 16b-3 |
Ascendis Pharma Management Efficiency
The company has return on total asset (ROA) of (0.2658) % which means that it has lost $0.2658 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6669) %, meaning that it generated substantial loss on money invested by shareholders. Ascendis Pharma's management efficiency ratios could be used to measure how well Ascendis Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Vittorio Colao | Verizon Communications | 57 | |
| Kim Goodman | Charter Communications | 53 | |
| Tom Montemagno | Charter Communications | 52 | |
| Richard Dykhouse | Charter Communications | 59 | |
| Tiffany McGowen | Paycom Software | N/A | |
| Eric Zinterhofer | Charter Communications | 47 | |
| Bradley Smith | Paycom Software | 53 | |
| Justin Long | Paycom Software | 45 | |
| Jay Carlson | Charter Communications | N/A | |
| Kristy Ross | Paycom Software | N/A | |
| Mike Bair | Charter Communications | 62 | |
| Samantha Hammock | Verizon Communications | 44 | |
| Magda Yrizarry | Verizon Communications | N/A | |
| Jessica Fischer | Charter Communications | 37 | |
| James Samford | Paycom Software | N/A | |
| Andre Veloso | Bemobi Mobile Tech | N/A | |
| Matthew Paque | Paycom Software | N/A | |
| Vandana Venkatesh | Verizon Communications | N/A | |
| Pedro Ripper | Bemobi Mobile Tech | 50 | |
| Gregory Maffei | Charter Communications | 58 | |
| Adam Ray | Charter Communications | N/A | |
Management Performance
| Return On Equity | -0.67 | |||
| Return On Asset | -0.27 |
Ascendis Pharma AS Leadership Team
Elected by the shareholders, the Ascendis Pharma's board of directors comprises two types of representatives: Ascendis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ascendis. The board's role is to monitor Ascendis Pharma's management team and ensure that shareholders' interests are well served. Ascendis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ascendis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Flemming Jensen, VP Quality | ||
| Scott Smith, Sr CFO | ||
| Michael LLM, Chief VP | ||
| Jan Mikkelsen, CEO and President | ||
| Birgitte MD, Sr Affairs | ||
| Timothy Lee, Director Relations | ||
| Lotte Sonderbjerg, Sr Officer | ||
| Peter Rasmussen, VP Officer | ||
| Kennett Sprogoe, VP Research | ||
| Jens Okkels, VP Devel |
Ascendis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ascendis Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.67 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (15.89) % | |||
| Current Valuation | 34.82 B | |||
| Shares Outstanding | 57.03 M | |||
| Price To Book | 0.90 X | |||
| Price To Sales | 1,080 X | |||
| Revenue | 7.78 M | |||
| Gross Profit | 4.25 M | |||
| EBITDA | (364.64 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Ascendis Stock
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.